SAN DIEGO – Mark Glassy, PhD, Chief Executive Officer and Co-founder of Nascent Biologics, Inc., (NBI), scientific researcher and inventor, announced today that he has recovered the license on his invention, “Pritumumab,” the first human antibody that has been used to treat cancer patients, after a 27 year absence in Japan.
Dr. Glassy invented Pritumumab, also known as CLNHII, CLNIgG and ACAII in the scientific community in 1982, while he was a faculty member at the University of California San Diego (UCSD) working as an Assistant Research Immunologist, Department of Medicine, Division of Hematology/Oncology. Shortly after he invented the antibody, it was taken by a visiting member of the faculty from Japan, who took it back to his country, had it licensed and used the antibody to treat a relative with cancer. Mark was told by the legal department at UCSD that there was no recourse available to retrieve the antibody since the Japanese party had already secured a license for the antibody from the University.
During the past 27 years in Japan, data has shown that approximately 250 brain cancer patients have been treated with Pritumumab. The response rate of this antibody is remarkable with an approx 30% response (after 5 years the survival rate of brain cancer is about 3%). Currently, there are people alive today that would have died had they not received this antibody.
In December, 2008, Mark was able to retrieve the license, and NBI finalized the license agreement with the Japanese scientist for Pritumumab in July 2009, returning it to the hands of the inventor and the United States, whereby numerous cancer patients will be treated for various types of cancer, including colon, brain, and pancreatic with a high rate of success.
“I am beyond pleased that we now own the license to Pritumumab, and know it will be beneficial in treating many victims of cancer in the United States,” Dr. Glassy remarked.
NBI will have Pritumumab manufactured for further clinical trials in the US under the sponsorship of the FDA and expects to begin these trials during late 2010. Pending satisfactory results NBI will then begin to market the antibody internationally for the treatment of other cancers such as colon, pancreatic, and breast cancers.
Nascent Biologics, cancer’s newest emeny, is a biotechnology company specializing in the commercialization of cytokine biology. Its mission is to nanoengineer molecular motors that will drive and boost the immune response.